These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34474304)

  • 1. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies.
    Kanan D; Kanan T; Dogan B; Orhan MD; Avsar T; Durdagi S
    ChemMedChem; 2021 Feb; 16(3):555-567. PubMed ID: 33063944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
    Qi SM; Cheng G; Cheng XD; Xu Z; Xu B; Zhang WD; Qin JJ
    Front Cell Dev Biol; 2020; 8():233. PubMed ID: 32300595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
    Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
    Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
    Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
    Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
    Turnbull AP; Ioannidis S; Krajewski WW; Pinto-Fernandez A; Heride C; Martin ACL; Tonkin LM; Townsend EC; Buker SM; Lancia DR; Caravella JA; Toms AV; Charlton TM; Lahdenranta J; Wilker E; Follows BC; Evans NJ; Stead L; Alli C; Zarayskiy VV; Talbot AC; Buckmelter AJ; Wang M; McKinnon CL; Saab F; McGouran JF; Century H; Gersch M; Pittman MS; Marshall CG; Raynham TM; Simcox M; Stewart LMD; McLoughlin SB; Escobedo JA; Bair KW; Dinsmore CJ; Hammonds TR; Kim S; Urbé S; Clague MJ; Kessler BM; Komander D
    Nature; 2017 Oct; 550(7677):481-486. PubMed ID: 29045389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity.
    He Y; Li W; Lv D; Zhang X; Zhang X; Ortiz YT; Budamagunta V; Campisi J; Zheng G; Zhou D
    Aging Cell; 2020 Mar; 19(3):e13117. PubMed ID: 32064756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.
    Brandão P; Loureiro JB; Carvalho S; Hamadou MH; Cravo S; Moreira J; Pereira D; Palmeira A; Pinto M; Saraiva L; Cidade H
    Eur J Med Chem; 2018 Aug; 156():711-721. PubMed ID: 30041135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USP7 small-molecule inhibitors interfere with ubiquitin binding.
    Kategaya L; Di Lello P; Rougé L; Pastor R; Clark KR; Drummond J; Kleinheinz T; Lin E; Upton JP; Prakash S; Heideker J; McCleland M; Ritorto MS; Alessi DR; Trost M; Bainbridge TW; Kwok MCM; Ma TP; Stiffler Z; Brasher B; Tang Y; Jaishankar P; Hearn BR; Renslo AR; Arkin MR; Cohen F; Yu K; Peale F; Gnad F; Chang MT; Klijn C; Blackwood E; Martin SE; Forrest WF; Ernst JA; Ndubaku C; Wang X; Beresini MH; Tsui V; Schwerdtfeger C; Blake RA; Murray J; Maurer T; Wertz IE
    Nature; 2017 Oct; 550(7677):534-538. PubMed ID: 29045385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HAUSP in both p53 wildtype and p53-mutant tumors.
    Tavana O; Sun H; Gu W
    Cell Cycle; 2018; 17(7):823-828. PubMed ID: 29616860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular recognition of p53 and MDM2 by USP7/HAUSP.
    Sheng Y; Saridakis V; Sarkari F; Duan S; Wu T; Arrowsmith CH; Frappier L
    Nat Struct Mol Biol; 2006 Mar; 13(3):285-91. PubMed ID: 16474402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STIP is a critical nuclear scaffolding protein linking USP7 to p53-Mdm2 pathway regulation.
    Ye M; Tang Y; Tang S; Liu J; Wu K; Yao S; Sun Y; Zhou L; Deng T; Chen Y; Huang C; Tan W
    Oncotarget; 2015 Oct; 6(33):34718-31. PubMed ID: 26460617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
    Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
    Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.
    Li P; Liu Y; Yang H; Liu HM
    Eur J Med Chem; 2021 Apr; 216():113291. PubMed ID: 33684824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small HDM2 antagonist peptide and a USP7 inhibitor synergistically inhibit the p53-HDM2-USP7 circuit.
    Mukherjee S; Saha G; Roy NS; Naiya G; Ghosh MK; Roy S
    Chem Biol Drug Des; 2023 Jul; 102(1):126-136. PubMed ID: 37105726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.